{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-22-000123","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.526202+00:00","generated_at":"2026-06-24T04:43:01.941200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q2 revenue $179.3M (+7% ex-divestitures); GAAP EPS -$0.18; cuts FY EPS guidance","bullets":["GAAP diluted EPS of $(0.18); adjusted EPS $0.04, down from $0.12 YoY.","GeneSight volumes up 39% YoY; hereditary cancer volumes down 4% YoY but stabilizing.","FY2022 revenue guidance unchanged at $670-$700M; adjusted EPS cut to $(0.10)-$0.00 from $0.00-$0.20.","Cash $283.6M; paid $48M qui tam settlement in Q2; no debt.","Launched Precise Oncology Solutions; liquid biopsy test via Illumina/Intermountain expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-22-000123","json":"https://secwatch.observer/filing/0000899923-22-000123.json","markdown":"https://secwatch.observer/filing/0000899923-22-000123.md","text":"https://secwatch.observer/filing/0000899923-22-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000123/0000899923-22-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000123/mygn-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:43:01.941200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}